Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

HDAC6 inhibition as potential new therapeutic strategy for ALS

Dec. 10, 2020

RGFP-963 demonstrates promise in mouse models of ALS

Dec. 10, 2020

QRA-244 could counteract disease progression due to hyperexcitability in patients with ALS

Dec. 9, 2020

Axsome reports phase II data on AXS-05 in patients with MDD with suicidal ideation

Dec. 9, 2020

New GBA2 inhibitors disclosed by Alectos Therapeutics

Dec. 9, 2020

Relmada initiates phase III program for REL-1017 as adjunctive therapy in MDD

Dec. 9, 2020

Positive data presented from global MOMENTUM trial of SRP-5051

Dec. 9, 2020

Natural killer cells kill aging cognition

Dec. 9, 2020

DoD grant to support evaluation of BXCL-501 for PTSD

Dec. 7, 2020

Interim analysis supports continuation of phase II/III GAIN trial of atuzaginstat in AD

Dec. 7, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 21, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 19, 2026
‘Detargeted’ targeted gene therapy improves activity in Pompe
BioWorld
A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...
WHO declares Ebola outbreak a public health emergency of international concern
BioWorld
The threat posed by the Ebola outbreak in the Democratic Republic of Congo has intensified, with the confirmation that it is caused by the Bundibugyo species of...
Nxera Pharma prepares and tests new GPR17 antagonists
BioWorld Science
Nxera Pharma UK Ltd. has identified new uracil nucleotide/cysteinyl leukotriene receptor (GPR17; P2Y-Like) antagonists potentially useful for the treatment of...